Background: Cystoid macular oedema (CME) is one of the important complications of uveitis leading to irreversible blindness. Currently, there is no gold standard treatment for this condition. The aim of this study was to investigate the effects of single intravitreal diclofenac (IVD) injection on short-term outcome of refractory uveitis-associated CME. Methods: This was a prospective clinical study on 16 consecutive patients (16 eyes) with refractory uveitis-associated CME. Intravitreal injection of 500 lg/ 0.1 ml of diclofenac sodium was given to the patients. The clinical outcomes considered were best-corrected visual acuity (BCVA) change and central macular thickness (CMT) changes in the pre-and postinjection periods. Follow-up examinations were performed at 1 and 4 weeks after the injection. Results: Age of the patients varied from 18 to 59 years (mean AE SD: 39.5 AE 13.2 years). Ten patients (62.5%) were females. Statistically significant differences were found in the decrease of mean BCVA (logMAR) (p = 0.043) and mean CMT (p = 0.003) during the study period. There was no significant difference in the intraocular pressure (IOP) increase at the end of the study (p = 0.94). Conclusion: Intravitreal diclofenac (IVD) may be a promising treatment for refractory uveitis-associated CME. Further clinical trials with a larger sample size should be conducted to confirm these findings and compare them with other treatments.
Introduction
Cystoid macular oedema (CME) is considered as one of the important complications of uveitis that can lead to visual impairment and irreversible blindness (Okhravi & Lightman 2003; Lardenoye et al. 2006; Kianersi et al. 2015) .
Uveitis-associated CME is often difficult to treat and may persist despite adequate control of the uveitis itself (Okhravi & Lightman 2003) .
Currently, there is no gold standard treatment for uveitis-associated CME. Several different medical and surgical treatment options with variable results, including topical, periocular, intravitreal and oral corticosteroids, topical and oral nonsteroidal anti-inflammatory drugs (NSAIDs), cyclosporin, methotrexate, chlorambucil, dexamethasone-cyclodextrin nanoparticle eye drops, pars plana vitrectomy and laser grid photocoagulation, have been used for treatment of uveitis-associated CME (de Vries et al. 1990 ; Conti & Kertes 2006; Das-Bhaumik & Jones 2006; Sallam et al. 2008; Taylor et al. 2009; Karim et al. 2013; Shulman et al. 2015) .
Therefore, there are no consensus and clear guidelines on the most effective treatment for this condition.
The exact pathophysiology of uveitis-associated CME is unclear, but there is evidence of constant release of inflammatory mediators as a first and most important step in CME (GuexCrosier 1999) .
Sodium diclofenac (SD) as a potent NSAID has been employed in the treatment of various ocular conditions, including macular oedema with different causes (Goa & Chrisp 1992; Soheilian et al. 2010) .
Sodium diclofenac (SD) was shown to exhibit anti-inflammatory effects via COX inhibitory activity and blocks both cyclooxygenase and lipo-oxygenase pathways similar to corticosteroids (Flach 2002) .
On the one hand, the subclinical intraocular inflammation is an important step in uveitis-associated CME formation (Okhravi & Lightman 2003) , and SD has been shown to reduce signs of ocular inflammation (Goa & Chrisp 1992) .
Hence, this is a clinical rationale for the use of SD for uveitis-associated CME, which could be a promising therapeutic option.
Few investigations with variable results have demonstrated the efficacy of IVD in the treatment of refractory uveitis-associated CME (Soheilian et al. 2010) . Soheilian et al. 2010 demonstrated that IVD improved visual acuity (VA) and decreased macular thickness in patients with uveitis-associated CME without causing major toxic effects.
However, other case series performed to evaluate the efficacy of single IVD injection for the treatment of uveitis-associated CME reported no significant improvement in VA and no significant reduction in CMT after 12, 24 and 36 weeks (Ramezani et al. 2013) .
Considering the variable results with IVD injection for treatment of uveitisassociated CME, we designed a study to investigate the functional and anatomical effects of single IVD injection on short-term outcome of refractory uveitis-associated CME (Ramezani et al. 2013 ).
Materials and Methods

Study design and participants
This was a prospective interventional clinical study of IVD on patients with refractory uveitis-associated CME conducted in Feiz ophthalmology Hospital (a referral center for eye disorders) affiliated to the Isfahan University of Medical Sciences (IUMS), Isfahan, Iran, between November 2015 and September 2016.
The protocol of the study was approved by the Institutional Ethics Committee of IUMS, Isfahan, Iran (Project No. 394806 ). Our study is registered at www.IRCT.ir (IRCT registration number: IRCT2016042727642 N1).
In addition, this study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
All participants were subjects with a diagnosis of refractory uveitis-associated CME that was resistant to treatment for at least 3 months and with BCVA between 20/50 and 5/200. We excluded pregnant or lactating patients; those with a history of glaucoma or ocular hypertension, monocularity, other diseases of the retina or the macula, intraocular or periocular injection during the last 6 months, any previous laser photocoagulation and/ or intraocular surgery (except cataract surgery), hypersensitivity reaction to NSAIDs; presence of vitreomacular traction (VMT) or epiretinal membrane (ERM); and patients who consumed any type of drugs that interfere with the metabolism of NSAIDs.
Exclusion criteria included not returning for the follow-up visits and initiation of any other topical or systemic medication by the patient.
The diagnosis of uveitis-associated CME was confirmed by slit-lamp biomicroscopy, indirect funduscopy, fluorescein angiography (FA) and optical coherence tomography (OCT) in all patients.
Refractory uveitis-associated CME was defined as CMT of >300 lm in the OCT without response to therapy for at least 3 months.
After adequate explanation about the study, informed consent was obtained prior to entry into the study from the patients.
Study interventions
One eye per patient was included the study. All patients received single dose of IVD injection. A commercially available ampule of diclofenac sodium (Troge Medical GMBH, Hamburg, Germany) (75 mg/3 ml) diluted with a balanced salt solution was used for each patient.
The injections were performed after topical anaesthesia with topical tetracaine (SinaDarou, Tehran, Iran) (0.5 g/ 100 ml). After insertion of the lid speculum, prepping and draping was performed using povidone-iodine. Then, 500 lg/0.1 ml of diclofenac sodium (Soheilian et al. 2010 ) was injected intravitreally using a 30-gauge needle with an insulin syringe in the superotemporal quadrant (4 mm and 3.50 mm posterior to the limbus for phakic eyes and pseudophakic eyes, respectively).
All injections were performed by the same ophthalmologist.
Outcome assessment
A change in BCVA in the pre-and postinjection periods was considered as the clinical outcome. Another outcome of the study was CMT changes in the OCT in the pre-and postinjection periods.
A complete medical history and complete ophthalmologic examination were performed before the study.
These examinations included measurement of BCVA (measured using a Snellen chart), anterior chamber inflammation (measured using a slitlamp biomicroscopy), assessment of lens opacity (measured using the Lens Opacities Classification System, version II (LOCS II) (Chylack et al. 1989) ) and measurement of IOP (using Goldmann tonometry).
A retinal thickness of 1 mm of the central retina was obtained as the CMT using a commercially available OCT (Heidelberg Engineering, Germany) through a dilated pupil by a retina specialist.
All patients also underwent FA (Heidelberg engineering) at baseline, prior to IVD injection.
Follow-up examinations were performed 1 day, 1 week and 4 weeks after the injections.
Serious injection-related complications such as retinal detachment, intravitreal haemorrhage, endophthalmitis and retinal tear were also recorded.
Statistical analysis
Statistical analyses were carried out using SPSS version 20.0 (SPSS, Inc., Chicago, IL, USA). P values less than 0.05 were considered significant. Snellen BCVA was transformed into logarithm of the minimum angle of resolution (BCVA logMAR).
Descriptive data were represented using mean AE SD, range and frequency (percentage).
The changes from baseline to 1 and 4 weeks of the study period were tested using general linear model (GLM).
Results
A total of 17 consecutive patients (17 eyes) with refractory uveitis-associated CME were assessed. One patient was excluded due to nasolacrimal duct obstruction, resulting in 16 patients (16 eyes) for the study. Age of the patients varied from 18 to 59 years (mean: 39.5 AE 13.2 years). Ten patients (62.5%) were females. Baseline characteristics of the patients are summarized in Table 1 .
Two patients had a history of autoimmunity (Behcet disease and sero-negative spondyloarthropathies), one patient had complicated CME after acute retinal necrosis and another patient had CME caused due to tuberculosis. Other patients had intermediate uveitis. One patient had diabetes mellitus in addition to intermediate uveitis.
The mean baseline CMT was 583.38 AE 130.86 (ranged 388-919). The outcomes of the study, including BCVA, CMT and IOP at baseline and at 1 and 4 weeks after IVD injections, are summarized in Table 1 .
The GLM revealed statistically significant differences in decrease of mean BCVA (logMAR) (p = 0.043) and mean CMT (p = 0.003) during the study period.
Mean BCVA (logMAR) AE SD decreased consistently, but there were no statistically significant differences at 1 week compared to baseline (p = 0.09) and at 4 weeks compared to 1 week (p = 0.32).
The Changes in mean CMT from baseline until the end of 4 weeks for all patients are shown in Fig. 1 .
Central macular thickness (CMT) decreased consistently during the study period (Fig. 2) . Statistically significant differences were observed at 1 week compared to baseline (p = 0.009), but there were no statistically significant differences at 4 weeks compared to 1 week (p = 0.31).
The mean AE SD CMT for all 16 eyes improved from 583.38 AE 130.86 to 488.94 AE 121.55 lm (p = 0.001) at the last visit (Table 1) .
There was no significant difference in the increase in IOP between the end of the study and at baseline (Table 1) .
Mean IOP of patients did not change significantly after intravitreal (IV) of DS. None of the cases developed intraocular hypertension (more than 22 mmHg), cataract, retinal detachment, retinal tear, endophthalmitis, vitreous haemorrhage or other complications during the study period. Only one patient developed inflammatory anterior chamber reaction that resolved after 2 weeks.
Discussion
The results of our study demonstrate that a single IVD injection of 500 lg was associated with a clinical improvement in BCVA and a reduction in CMT in patients with refractory uveitis-associated CME compared with baseline. There are at least four possible pathophysiologic mechanisms in uveitis-associated CME, including persistent subclinical inflammation, vitreomacular mechanical interactions, Frank membrane formation on the macular surface and retinal pigment epithelial (RPE) ion pump dysfunction as a consequence of chronic inflammation (van Kooij et al. 2006; Cho & Madu 2009 ).
The inflammatory response results in biosynthesis of PG and thromboxane (TXA) by COX1 and COX2 (FitzGerald & Patrono 2001) . Prostaglandin E2, the major PG in the retina (Preud '-homme et al. 1985) , in addition to its role as an inflammatory mediator, induces the expression of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor, which increases the vascular permeability of vessels and promotes vascular leakage (Cheng et al. 1998) . Finally, following the pathophysiologic mechanisms, there is impairment in the inner blood-retinal barrier integrity (Cordero Coma et al. 2007) .
It has been demonstrated that PG plays an important role in CME after cataract surgery (Fine et al. 2001; van Kooij et al. 2006) .
Hence, SD, through the inhibition of the biosynthesis of PG and controlling the intraocular inflammation, may be a promising treatment of such cases (Miyake & Ibaraki 2002; Ahuja et al. 2008) .
Treatment with intravitreal SD had been described earlier in the experimental study (Shen et al. 2000) . Shen et al. investigate the effect of diclofenac formulated in hyaluronan (diclofenac/ HA) on angiogenesis in vitro and its intraocular toxicity in vivo. They demonstrated IV injection of 540 lg or higher doses of diclofenac/HA resulted in ocular toxicity including cataract, vitreous haze and retinal damage, but no toxicity was observed in the eyes that received 400 lg or less diclofenac/HA (Shen et al. 2000) .
Although regarding the study of Shen et al., some concern can be considered about the too small window of therapeutic and potential toxic levels of diclofenac, human studies had been used the IV SD with dose of 500 lg/0.1 without significant side-effect and toxicity (Soheilian et al. 2010 (Soheilian et al. , 2013a . Soheilian et al. (2010) had reported that IVD has beneficial effects on CME with various aetiologies, including uveitis (Soheilian et al. 2010) .
A randomized clinical trial comparing the clinical efficacy of IVD versus IV triamcinolone demonstrated that eyes with refractory uveitis-associated CME receiving a single IV triamcinolone showed a significant improvement in comparison with baseline in terms of both BCVA and CMT. Although 50% of the IVD-injected eyes showed improvement in VA and CMT reduction, within-group analysis showed no statistically significant changes in both BCVA and CMT in this group. Moreover, comparing the mean BCVA and CMT changes revealed no significant difference between the groups at any of the follow-up visits (Soheilian et al. 2013a,b) .
Such inferiority was also observed by Elbendary and Shahin in diabetic macular oedema cases, probably due to the pharmacokinetics of SD in the intraocular environment (Elbendary & Shahin 2011 ) and the rapid elimination and short half-life of SD after IV injection in the vitreous humour due to its low molecular weight (Durairaj et al. 2009 ). Therefore, repeated injections versus single injection might be a solution for the short half-life of SD in the vitreous humour and can improve the clinical outcome.
The beneficial effects of NSAIDs over corticosteroids include stabilization of IOP and reduction in the risk of secondary infections (Flach 2002; Hsu et al. 2003) .
In the present study, we did not observe any beneficial effect of IVD in terms of BCVA improvement; however, mean CMT diminished to a significant level at 1 week. In contrast, mean BCVA logMAR decreased from baseline at 1 month after IVD injection, which was comparable to a high reduction in mean CMT, which might be due to a better and faster anatomical effect of IVD rather than the functional effect following IVD injection. This study also showed that there were more earlier effects on CMT compared with BCVA. Several studies have also found poor correlation between CMT and BCVA in eyes with macular oedema of various aetiologies (Catier et al. 2005) .
Improvement in BCVA depends on several factors besides CMT, including the duration of oedema, perfusion of macular capillaries, photoreceptor impairment, RPE dysfunction and media opacities (Johnson 2009 ).
However, overall, the side-effect profile for IVT includes cataract and elevation of IOP, and even potential endophthalmitis is considerable (Jonas 2006) . However, IVD for refractory uveitisassociated CME presents some potential disadvantages, most particularly the shorter half-life in the vitreous humour when compared with IVT, but a major advantage of IVD is at the least the low theoretical risk of adverse side-effects, including increase in IOP. Therefore, it seems reasonable to use IVD as an adjunctive treatment or to avoid potential complications of IVT as an alternative agent in the treatment of uveitic CME.
Our study is limited by the small number of eyes, a short-term follow-up and the lack of a control group; hence, further studies are needed to confirm these findings.
Conclusion
This study suggests that IVD may be a promising treatment for refractory uveitis-associated CME. Further clinical trials with larger sample sizes should be conducted to confirm these findings and compare them with other treatments.
(A) (B) (C) Fig. 2 . Optical coherence tomography at baseline (A), 1 week (B) and 4 weeks (C) after intravitreal diclofenac injection in a refractory uveitisassociated cystoid macular oedema case.
